{
  "id": 3618713,
  "title": "Mesoblast FY2026 slides: $115M revenue marks commercial transition",
  "url": "https://urgent.news/2026/08/26/mesoblast-fy2026-slides-115m-revenue-marks-commercial-transition",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-26T23:45:03.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/mesoblast-fy2026-slides-115m-revenue-marks-commercial-transition-93CH-4878095"
  },
  "original_language": "en",
  "account": "Mesoblast Limited, a biotech company transitioning to commercial drug manufacturing, reported US$115 million in net revenue for the fiscal year ending June 30, 2026 - its first full year of RYONCIL sales. CEO Silviu Itescu highlighted the significant commercial progress, with the drug achieving an 84% survival rate in pediatric patients. Despite solid revenue performance, shares fell slightly in regular trading due to continued losses and a 2.5% revenue miss. The company invested US$39.7 million in research and development, focusing on Phase 3 clinical trials and manufacturing capacity. Mesoblast secured new capital, including a US$125 million credit line, to support its growth. The company also announced a registration trial for expanding RYONCIL's usage to adult patients with SR-aGvHD, and a Phase 3 trial for chronic low back pain, demonstrating strong market potential.",
  "summary": null,
  "key_points": [
    "Mesoblast reported $115M revenue for FY2026, marking commercial transition",
    "RYONCIL drug achieved 84% survival rate in pediatric patients",
    "Company secured $125M credit line and new capital for growth"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}